Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a complex, progressive primary neurodegenerative disease. Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) has remained the strongest single genome-wide associated risk variant in AD. Scientific advances in APOE biology, AD pathophysiology and ApoE-targeted therapies have brought APOE to the forefront of research, with potential translation into routine AD clinical care. This contemporary Review will merge APOE research with the emerging AD clinical care pathway and discuss APOE genetic risk as a conduit to genomic-based precision medicine in AD, including ApoE’s influence in the ATX(N) biomarker framework of AD. We summarize the evidence for APOE as an important modifier of AD clinical–biological trajectories. We then illustrate the utility of APOE testing and the future of ApoE-targeted therapies in the next-generation AD clinical–diagnostic pathway. With the emergence of new AD therapies, understanding how APOE modulates AD pathophysiology will become critical for personalized AD patient care. This Review provides a framework for incorporating APOE into Alzheimer’s disease (AD) clinical care by bridging recent advances in APOE and AD research with emerging clinical applications for APOE testing and ApoE-targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“However, switching from the APOE ε4 to the APOE ε2 allele could have deleterious consequences in the periphery given the association with type III hyperlipoproteinemia 12 (Fig.”
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Furthermore, [ 18 F]fluorodeoxyglucose PET measures showed that APOE ε4 carriers had lower cerebral glucose metabolism, correlating with Aβ pathology, brain atrophy and cogni tive measures across multiple stages of AD 115 .”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · cited 1×
“Since the first genomewide association studies in AD, at least 75 risk loci in addition to APOE have been associated with AD 138,139 , which can be incorporated in the PRS to improve AD risk determination 130,131 .”
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citationProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“By contrast, APOE ε2 remains the strongest genetic protective factor against sporadic AD 7,8 , with very few APOE ε2 / ε2 individuals developing AD up to the age of 90 years 14,18 .”
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 12×
“A small percentage of EOAD is caused by familial autosomal dominant mutations (ADAD; autoso mal dominant AD), while the morecommon LOAD is attributed to a combination of genetic susceptibility and environmental factors 4 .”
InfluentialAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 2×
“APOE ε4 carriers show changes in multiple vascular biomarkers, including decreased cerebral blood flow, increased BBB breakdown, more white matter intensities, evidence of CAA and increased levels of CSF sPDGFRβ 105,106 .”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 4×
“4a), there is an APOE ε4 > ε2 > ε3 effect on the onset and extent of Aβ deposition in animal models 31,32,57 .”
InfluentialSelf-citationApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 6×
“In vitro and mouse model studies have shown that ApoE4 increases tau hyperphospho rylation and aggregation 48,79,80 , causing neurodegeneration in the absence of Aβ as mediated by microglial activation 48,79,80 (Fig.”
InfluentialSelf-citation
Cited by
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
“2 was the first and most significant LOAD risk locus identified in AD (Narasimhan et al. 2024).”
Wei, P., Lin, K., Chen, X., Fang, C., Qiu, L., Hu, J., & Chang, J. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70306 · Cited by 11
“The extensive involvement of APOE4 in AD has led some scholars to propose the “APOE Cascade Hypothesis” to address the impact of APOE4 on AD [24, 25].”
Perks, C. M., Barker, R. M., Alhadrami, M., Alkahtani, O., Gill, E., Grishaw, M., Harland, A. J., Henley, P., Li, H., O’Sullivan, E., et al. (2025) · Genes · doi:10.3390/genes16030331 · Cited by 11
Musso, G., Cosma, C., Moz, S., Gabelli, C., Navaglia, F., Codemo, A., Zambon, C. F., Cagnin, A., Antonini, A., Corbetta, M., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120659 · Cited by 6
Metadata
- Authors
- Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H.
- Venue
- Nature Neuroscience
- Published
- 2024-06-19
- Volume
- 27
- Issue
- 7
- Pages
- 1236-1252
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W4399810054
- Cited by
- 66
- References
- 92
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway. https://app.cochat.ai/papers/10.1038/s41593-024-01669-5
- The paper
- Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H. (2024). Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway. Nature Neuroscience. https://doi.org/10.1038/s41593-024-01669-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.